Bristol Myers schizophrenia therapy safe in late-stage trial

hapabapa/iStock Editorial via Getty Images

Bristol Myers Squibb (NYSE:BMY) announced Saturday that its experimental schizophrenia therapy KarXT, acquired as part of its recent Karuna Therapeutics buyout, indicated a well-tolerated safety profile in a Phase 3 program.

Citing data from its EMERGENT-4 and EMERGENT-5 trials, the Princeton, New

BristollatestageMyersSafeschizophreniatherapytrial
Comments (0)
Add Comment